

Suvorexant Formulation

Version 2.16 Revision Date: 2021/04/09 SDS Number: 21536-00018 Date of last issue: 2020/10/16
Date of first issue: 2014/10/14

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Suvorexant Formulation

Manufacturer or supplier's details

Company : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION**GHS Classification**

Long-term (chronic) aquatic hazard : Category 3

GHS label elements

Hazard pictograms : None

Signal word : None

Hazard statements : H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P273 Avoid release to the environment.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Suvorexant	1030377-33-3	>= 2.5 -< 10

SAFETY DATA SHEET



Suvorexant Formulation

Version 2.16 Revision Date: 2021/04/09 SDS Number: 21536-00018 Date of last issue: 2020/10/16
Date of first issue: 2014/10/14

Magnesium stearate	557-04-0	< 10
--------------------	----------	------

4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency measures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal pro-

Suvorexant Formulation

Version 2.16 Revision Date: 2021/04/09 SDS Number: 21536-00018 Date of last issue: 2020/10/16
 Date of first issue: 2014/10/14

Suvorexant	1030377-33-3	TWA	20 µg/m3 (OEB 3)	Internal
		Wipe limit	200 µg/100 cm ²	Internal
Magnesium stearate	557-04-0	NAB	10 mg/m3	ID OEL
Further information: Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals				
		TWA (Inhalable particulate matter)	10 mg/m3	ACGIH
		TWA (Respirable particulate matter)	3 mg/m3	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type
 Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.
 Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures,

Suvorexant Formulation

Version 2.16 Revision Date: 2021/04/09 SDS Number: 21536-00018 Date of last issue: 2020/10/16
Date of first issue: 2014/10/14

industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable

Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/16
2.16	2021/04/09	21536-00018	Date of first issue: 2014/10/14

Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Components:**Suvorexant:**

Acute oral toxicity	:	LD50 (Rat): > 1,200 mg/kg LD50 (Dog): > 1,125 mg/kg LDLo (Mouse): 2,000 mg/kg
---------------------	---	---

Magnesium stearate:

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Suvorexant Formulation

Version 2.16 Revision Date: 2021/04/09 SDS Number: 21536-00018 Date of last issue: 2020/10/16
Date of first issue: 2014/10/14

Components:**Suvorexant:**

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Suvorexant:**

Species : Bovine cornea
Result : Mild eye irritation
Method : Bovine cornea (BCOP)

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Suvorexant:**

Test Type : Local lymph node assay (LLNA)
Species : Mouse
Assessment : Does not cause skin sensitisation.
Result : negative

Magnesium stearate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Suvorexant Formulation

Version Revision Date: SDS Number: Date of last issue: 2020/10/16
2.16 2021/04/09 21536-00018 Date of first issue: 2014/10/14

Components:**Suvorexant:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Result: negative

Test Type: Micronucleus test
Species: Rat
Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Suvorexant:**

Species : Mouse
Application Route : Oral
Exposure time : 6 month(s)
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Suvorexant Formulation

Version 2.16 Revision Date: 2021/04/09 SDS Number: 21536-00018 Date of last issue: 2020/10/16
Date of first issue: 2014/10/14

Reproductive toxicity

Not classified based on available information.

Components:**Suvorexant:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
General Toxicity - Parent: NOAEL: \geq 325 mg/kg body weight
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rabbit, female
Application Route: Oral
Developmental Toxicity: NOAEL: 150 mg/kg body weight
Result: negative

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 80 mg/kg body weight
Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

Components:**Suvorexant:**

Remarks : Based on human experience.

STOT - repeated exposure

Not classified based on available information.

Components:**Suvorexant:**

Exposure routes : Ingestion

Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/16
2.16	2021/04/09	21536-00018	Date of first issue: 2014/10/14

Target Organs : Central nervous system
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Suvorexant:

Species : Rat
 NOAEL : 325 mg/kg
 LOAEL : 1,200 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Blood, Pancreas

Species : Dog
 NOAEL : 50 mg/kg
 LOAEL : 125 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Blood, Liver, Central nervous system

Species : Rat
 NOAEL : 75 mg/kg
 LOAEL : 300 mg/kg
 Application Route : Oral
 Exposure time : 180 d
 Target Organs : Pancreas, Blood, Stomach

Species : Dog
 NOAEL : 50 mg/kg
 LOAEL : 125 mg/kg
 Application Route : Oral
 Exposure time : 270 d
 Target Organs : Blood

Species : Rat
 NOAEL : 40 mg/kg
 LOAEL : 80 mg/kg
 Application Route : Oral
 Exposure time : 18 Months
 Target Organs : Eye, Central nervous system

Magnesium stearate:

Species : Rat
 NOAEL : > 100 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days
 Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Suvorexant Formulation

Version 2.16 Revision Date: 2021/04/09 SDS Number: 21536-00018 Date of last issue: 2020/10/16
 Date of first issue: 2014/10/14

Experience with human exposure**Components:****Suvorexant:**

Ingestion : Symptoms: Drowsiness, Headache, abnormal dreams, Fatigue, Dizziness, dry mouth, Nausea, liver function change, upper respiratory tract infection, urinary tract infection, Cough, Diarrhoea, Palpitation, tachycardia

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Suvorexant:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Mysidopsis bahia (opossum shrimp)): 0.56 mg/l
 Exposure time: 96 h
 Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 5 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.5 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 1

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.14 mg/l
 Exposure time: 32 d
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.5 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
 Exposure time: 48 h

Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/16
2.16	2021/04/09	21536-00018	Date of first issue: 2014/10/14

Method: DIN 38412
 Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
 Exposure time: 47 h
 Test substance: Water Accommodated Fraction
 Method: Directive 67/548/EEC, Annex V, C.2.
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
 Exposure time: 16 h
 Test substance: Water Accommodated Fraction
 Remarks: Based on data from similar materials

Persistence and degradability**Components:****Suvorexant:**

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 81 %
 Exposure time: 28 d
 Method: OECD Test Guideline 314

Stability in water : Hydrolysis: < 10 %(5 d)
 Method: OECD Test Guideline 111

Magnesium stearate:

Biodegradability : Result: Not biodegradable
 Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Suvorexant:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
 Bioconcentration factor (BCF): 358

Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/16
2.16	2021/04/09	21536-00018	Date of first issue: 2014/10/14

Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.04

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Other adverse effectsNo data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC CodeNot applicable for product as supplied.

15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture****Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.****Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health**

Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/16
2.16	2021/04/09	21536-00018	Date of first issue: 2014/10/14

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

Regulation of the Minister of Trade No. 44 of 2009 on Procurement, Distribution and Supervision of Hazardous Materials

Type of Hazardous Materials Restricted to Import, Distribution and Supervision : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ID OEL : Indonesia. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average

ID OEL / NAB : Long term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect

Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/16
2.16	2021/04/09	21536-00018	Date of first issue: 2014/10/14

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN